Table 2 Cytogenetic profiles of patients based on interphase fluorescent in situ hybridization (n = 930)

From: Natural history of multiple myeloma with de novo del(17p)

Cytogenetic abnormality

De novo del(17p) (n = 310)

All control patients (n = 620)

High-risk translocation (n = 79)

Standard-risk (n = 541)

P a

t(4;14)

48 (15.5)

49 (7.9)

49 (62.0)

–

<0.001

t(6;14)b

4 (1.7)

7 (1.5)

–

7 (1.7)

1.000

t(11;14)

45 (14.5)

131 (21.1)

–

131 (24.2)

0.016

t(14;16)

24 (7.7)

22 (3.2)

22 (27.8)

–

0.009

t(14;20)b

3 (1.2)

9 (1.9)

9 (13.8)

–

0.760

Unspecified immunoglobulin heavy chain (IgH) rearrangement/IgH variable region deletion

19 (6.1)

56 (9.0)

–

56 (10.3)

0.159

Any trisomy or tetrasomy

154 (49.7)

345 (55.6)

31 (39.2)

314 (58.0)

0.002; 0.094

Hyperdiploidy

112 (36.1)

276 (44.5)

16 (20.2)

260 (48.1)

0.016; <0.001

Del (13q) and/or monosomy 13

200 (64.5)

257 (41.4)

64 (81.0)

193 (35.7)

<0.001; <0.001

Del (13q)

39 (12.6)

51 (8.2)

11 (13.9)

40 (7.4)

0.045; 0.017

Monosomy 13

163 (52.6)

213 (34.3)

57 (72.5)

156 (28.8)

<0.001; <0.001

1q22 gainc

21 (29.2)

38 (31.1)

11 (68.7)

27 (25.5)

0.872; 0.003

Del (1p31)c

4 (5.6)

1 (0.8)

1 (6.2)

0 (0)

0.064; 0.021

  1. ap-value for Fischer’s exact test. Comparison between del(17p) and all controls when only one value is present and the second value when present represents comparison across del(17p), high-risk translocation and standard-risk groups
  2. bCalculation is limited to patients who had FISH after May 2009 (n = 716) when probes for these abnormalities were introduced
  3. cCalculation limited to patients who had FISH after August 2014 (n = 194) when probe for 1q gain and del (1p) were introduced
Back to article page